Our research teams have made significant basic science contributions to the study of infectious disease-causing organisms and are paving the way for new therapies.
Chelsie E. Armbruster, PhD, associate professor of microbiology and immunology, has been honored with a 2024-2025 Distinguished Postdoc Mentor Award from The Graduate School at the University at Buffalo.
An NIH grant will allow Chelsie E. Armbruster, PhD, to study pathogens than cause urinary tract infections, the most common infections worldwide and a leading cause of morbidity and health care expenditures across all ages.
New research reveals that triggering a cell’s DNA damage response could be a promising avenue for developing novel treatments against several rare but devastating viruses for which no antiviral treatments exist.
Two doctoral candidates at the Jacobs School of Medicine and Biomedical Sciences have received 2024 predoctoral fellowships with two years of funding from the American Heart Association (AHA).
One of the most dramatic success stories in modern medicine is the treatment of cystic fibrosis (CF), where therapeutic breakthroughs have dramatically reduced patients’ symptoms and increased their life expectancies.
The urothelial glycosaminoglycan layer: composition and contribution to pathogen fitness during catheter-associated urinary tract infection. Chelsie Armbruster (Principal Investigator). NIH/NIDDK. $3,045,103. 6/1/2024-4/1/2029.
Virologic and immunologic impacts of active viral persistence in lung AMs of HIV-1-infected, cART-suppressed individuals. Saikat Boliar (Principal Investigator). NIAID. $2,915,905. 5/1/2024-3/1/2029.
Disease progression modeling of bladder cancer. Yijun Sun (Co-Principal Investigator). NIH. $2,507,223. 9/1/2022-8/1/2028.